Compare Micron Technology, Inc. (MU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Micron Technology, Inc. trades at $982.44 (market cap $977.44B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Micron Technology, Inc. is far larger — about 638.8× Recursion Pharmaceuticals Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MU | RXRX | |
|---|---|---|
Market Cap | $977.44B | $1.53B |
Sector | Technology | Health |
52-Week High | $1.21K | $6.79 |
52-Week Low | $104.88 | $2.84 |
Enterprise Value | $957.80B | $946.50M |
Dividend Yield | 0.06% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
